A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

This study is currently recruiting participants.

Verified March 2013 by Institut National de la Santé Et de la Recherche Médicale, France

Study NCT01567540 Information provided by Institut National de la Santé Et de la Recherche Médicale, France

First Received on March 2, 2012. Last Updated on May 14, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Hepatitis C

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

Sitagliptin

Additional drug interventions recognized in this trial

More general drug interventions related to this trial

Sponsors listed in this trial